Tarsus Pharmaceuticals, Inc.
TARS
$59.10
-$0.73-1.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 54.01% | 42.52% | 39.59% | 38.70% | 29.19% |
| Total Depreciation and Amortization | 26.71% | 48.24% | 58.33% | 48.09% | 35.67% |
| Total Amortization of Deferred Charges | 20.91% | 23.03% | 26.37% | 29.27% | 21.29% |
| Total Other Non-Cash Items | 59.10% | 36.86% | 14.24% | 2.59% | 31.03% |
| Change in Net Operating Assets | -222.85% | 280.80% | -168.95% | -6,262.45% | 253.04% |
| Cash from Operations | 75.03% | 85.00% | 46.13% | 34.72% | 50.58% |
| Capital Expenditure | -660.82% | -529.16% | -139.00% | -22.48% | -48.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 61.02% | 83.68% | -22.54% | -85.86% | -557.15% |
| Cash from Investing | 50.17% | 78.86% | -23.97% | -84.56% | -587.02% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | 1,400.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.38% | 35.67% | 17.53% | -35.91% | -34.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 99.85% | -478.00% |
| Cash from Financing | -95.60% | -7.29% | -16.03% | -48.47% | -22.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -382.95% | 169.63% | -20.73% | -210.17% | -112.02% |